A Phase II randomized, double-blind, sham surgery-controlled study of the efficacy and safety of intraputaminal AAV2-GDNF in the treatment of adults with moderate PD (REGENERATE-PD) is currently enrolling participants in the USA [114]. Here, GDNF is linked to Parkinson disease.